Develop high-quality targeted innovative drugs to create new therapeutic options for patients worldwide.
Responsibility achieves quality, efficiency creates excellence, and innovation leads the future.
Fochon Biosciences is headquartered in Liang Jiang New Area, Chongqing, and has international presence in Shanghai, Beijing and San Francisco. We efficiently promote our R&D programs by leveraging global resources.
The R&D team of Fochon Biosciences, originally from Fochon Pharmaceuticals, has profound experience in pharmaceutical research and development. Since its establishment in 2009, the team has successfully developed more than ten proprietary small molecule targeted innovative drugs, including FCN-005, SAF-189, FCN-437c, FCN-338 (LOXO-338; Eli Lilly is authorized to develop and commercialize FCN-338 in all countries and regions excluding Mainland China, Macao SAR, and Hong Kong SAR) .